Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men - Wikidata - awgldk - TriplyDB

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men

http://www.wikidata.org/entity/Q35054958

about

Insights on common vaccinations in HIV-infection: efficacy and safety Oral human papillomavirus infection and head and neck cancers in HIV-infected individuals The rising challenge of non-AIDS-defining cancers in HIV-infected patients Screening guidelines for non-AIDS defining cancers in HIV-infected individuals Safety of human papillomavirus vaccines: a review Anal dysplasia in HIV-infected women: a commentary on the field.Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States Safety and immunogenicity of the quadrivalent human papillomavirus (qHPV) vaccine in HIV-positive Spanish men who have sex with men (MSM)Vaccination in HIV-infected adults.Update on opportunistic infections in the era of effective antiretroviral therapy Guidelines for the prevention and treatment of opportunistic infections in HIV-exposed and HIV-infected children: recommendations from the National Institutes of Health, Centers for Disease Control and Prevention, the HIV Medicine Association of the Cervical human papillomavirus infection among young women engaged in sex work in Phnom Penh, Cambodia: prevalence, genotypes, risk factors and association with HIV infection.2013 IDSA clinical practice guideline for vaccination of the immunocompromised host.Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America Prevalence and risk factors for neutralizing antibodies to human papillomavirus types 16 and 18 in HIV-positive men who have sex with men Immunogenicity and safety of the quadrivalent human papillomavirus vaccine in HIV-1-infected women.Human papilloma virus vaccines: Current scenario Anal Human Papillomavirus Genotyping among HIV-Positive Men Who Have Sex with Men in Xi'an, China Prevalence of Anal Human Papillomavirus Infection and Risk Factors among HIV-positive Patients in Tokyo, Japan.Immunogenicity of quadrivalent human papillomavirus vaccine in organ transplant recipients.A review of clinical trials of human papillomavirus prophylactic vaccines.HPV vaccine coverage among men who have sex with men - National HIV Behavioral Surveillance System, United States, 2011 Prevalence of non-HIV cancer risk factors in persons living with HIV/AIDS: a meta-analysis.Cumulative Incidence of Cancer Among Persons With HIV in North America: A Cohort Study.Humoral, mucosal, and cell-mediated immunity against vaccine and nonvaccine genotypes after administration of quadrivalent human papillomavirus vaccine to HIV-infected children Cancer prevention in HIV-infected populations.Impact of the HIV epidemic on the incidence rates of anal cancer in the United States.The Human Papillomavirus Vaccine: Current Perspective and Future Role in Prevention and Treatment of Anal Intraepithelial Neoplasia and Anal Cancer.High-grade anal intraepithelial neoplasia among HIV-1-infected men screening for a multicenter clinical trial of a human papillomavirus vaccine.The role of viral co-infection in HIV-associated non-AIDS-related cancers Comparison of the immunogenicity of Cervarix® and Gardasil® human papillomavirus vaccines for oncogenic non-vaccine serotypes HPV-31, HPV-33, and HPV-45 in HIV-infected adults.Time trends in cancer incidence in persons living with HIV/AIDS in the antiretroviral therapy era: 1997-2012.Prophylactic HPV vaccination and anal cancer Human Papillomavirus (HPV) Infections and the Importance of HPV Vaccination.Role and uptake of human papillomavirus vaccine in adolescent health in the United States Anal cancer and cervical cancer screening: key differences.Human papillomavirus vaccination in males: the state of the science.Vaccination to protect against infection of the female reproductive tract.Primary prophylactic human papillomavirus vaccination programs: future perspective on global impact.Clinical trials of human papillomavirus vaccines and beyond.

P2860

Q26770665-D25B75FE-BDC4-4278-A3B7-A6B109FD749F Q26825257-B0313D2E-4D91-4229-B2F5-F2B61C9C6BC5 Q26861496-CD91F599-FAC9-460B-BE47-39CC8628F727 Q27021899-B4DF1E40-059C-4004-9327-1183CAFC48B2 Q28082119-76C0C21D-DF7A-4751-A1A5-0101B2407738 Q30252055-517354E9-42FD-48D9-9DBA-614B46230A7D Q33166996-BF8C083E-CACD-42E5-96A0-E1A26A8DA167 Q33916553-FE0CFA81-F6F4-41BF-B498-102E7DD972B3 Q33980764-883B03B4-6A48-4866-8C05-3B9A97CB28D3 Q34085853-86D3A531-2A99-4B1A-8729-C34D76708BE1 Q34212799-ABC27120-01DA-4476-891C-37BF39DEB61A Q34354553-32AD97E3-00FD-4DE7-8A1F-527BCF4B1319 Q34390072-469A0639-B145-4CEC-AF05-A7666EA08162 Q34635523-47AB8B97-9BB2-4005-97F1-A8E9D9DA81C4 Q34873067-C38628B3-B483-4714-B018-5D5596EDEDAF Q35008398-C93BA1EC-35E4-49E0-B9B2-7E7F0057F927 Q35366075-D96B95F2-98D9-4BE8-9379-FDFE3C1BC303 Q35553220-E09A5153-199F-437C-AEDB-015FB7931003 Q35773936-5D100FDC-A3D3-4069-8070-E7773C3F0AE0 Q36093327-84702100-F5B9-4EDC-B43E-E44EEB3DE9B3 Q36259403-FE7DF78E-A998-4DDC-866F-CE46D3C1A4B5 Q36368353-313BCE22-7232-496C-B646-C47AF437ED61 Q36399193-339F1BE9-FC3C-40C2-A07C-D222F016ABEC Q36459660-FC54EA5E-01BE-4716-90E6-62E0C93CF183 Q36486823-F3038D31-7C52-48A4-AF20-F8A792BF1402 Q36680086-ACCAA6DD-DEF5-4FBA-87DF-4DF14B005373 Q36727400-87DFF5CD-CAAE-45CC-9DA7-F13D56ABD29D Q36788317-63CE6028-41DA-4A81-A2CB-59C3BEBB9DD3 Q36911916-1385B02A-DEDA-4008-BF26-59F28ED9EE8D Q36960884-8B4EF030-8761-4094-B1C4-96D3305869C6 Q36977831-3499C132-07A9-4C3A-85D2-F3C9C86C12A7 Q37047999-4D4C61B2-A4E7-4C79-895E-19D97BEBFECC Q37135065-463C3904-C852-4717-A9AB-4BB9D1D02340 Q37155765-99CD7ACE-6105-497A-AC7B-2C765325DD07 Q37244355-FE07B5DF-0275-4EFA-AB40-123CDE79320D Q37841421-CD67F1CF-48A9-464E-BBF8-3F9491C5052E Q37848732-A10AE2F7-AD37-4F9E-92CA-9C72A03489CC Q37849708-37D6BAA6-0F21-49FF-A5D1-5BADAF6B1AE7 Q37912228-AE91EB20-DD70-4BBF-BC3A-F221A54D95D2 Q38111962-CF491B23-F5B4-4A22-AF25-2ED9C7548FC7

P2860

Safety and immunogenicity of the quadrivalent human papillomavirus vaccine in HIV-1-infected men

http://www.wikidata.org/entity/Q35054958

description

2010 nî lūn-bûn

@nan

2010 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած

@hyw

2010 թվականի հոտեմբերին հրատարակված գիտական հոդված

@hy

2010年の論文

@ja

2010年論文

@yue

2010年論文

@zh-hant

2010年論文

@zh-hk

2010年論文

@zh-mo

2010年論文

@zh-tw

2010年论文

@wuu

name

Safety and immunogenicity of t ...... vaccine in HIV-1-infected men

@ast

Safety and immunogenicity of t ...... vaccine in HIV-1-infected men

@en

type

label

Safety and immunogenicity of t ...... vaccine in HIV-1-infected men

@ast

Safety and immunogenicity of t ...... vaccine in HIV-1-infected men

@en

prefLabel

Safety and immunogenicity of t ...... vaccine in HIV-1-infected men

@ast

Safety and immunogenicity of t ...... vaccine in HIV-1-infected men

@en

P1433

Q35054958-E3A9C961-1F95-4C09-A256-35ED6EC3A67C

P1476

Q35054958-6D5B7539-7EF8-4DCA-AF20-570F69933380

P2093

Q35054958-0231205F-3757-4B82-A81A-15FC6E71BBC7

Q35054958-068D027C-440A-45EB-AE0E-C494D7AB0523

Q35054958-343994B7-211D-4E3F-84C6-B79551BADAC7

Q35054958-3AE8A800-3E1B-4C6A-8D48-A835B2E4747B

Q35054958-4BA33E95-EA00-4545-9BAA-0BA741D3E940

Q35054958-5D9BDFA1-7164-4D1A-ADF7-F4D4A159F296

Q35054958-6E6C56B4-FB7F-4B17-8B0B-9369233454C2

Q35054958-77A9B309-67DB-4CF3-AE8F-C7E444187DA8

Q35054958-83A24D92-7B14-4C0E-B53E-CB911BC25E39

Q35054958-B012D25D-A7EF-4B54-8218-D6BD78D12E47

P2860

Q35054958-02D4C38A-2421-4CBF-8015-A8D9752A69E2

Q35054958-0933F1AE-778C-47B9-B96B-400C334CF924

Q35054958-113CEF86-1542-4D2F-B4DE-BA5297063E09

Q35054958-195F1564-BB5B-482E-87F4-1C356F727924

Q35054958-34361FFA-109C-485C-81F3-35AEB32FDBD8

Q35054958-44B87705-B9AD-4CBA-85F2-D9E84E56D87F

Q35054958-4B2EFE78-D4CB-41A4-BD0B-DC8D08688F37

Q35054958-55B4CBA3-C2CD-44AC-BDDD-9E9EE789F3B9

Q35054958-5F80AF0F-0524-46D5-8F16-E31C8EA6E7F8

Q35054958-67EEA35D-93C6-463C-82A4-7FE9D553BE7F

P304

Q35054958-7EE945B2-2C0C-45C2-AF4E-3E901823C116

P31

Q35054958-5A00D42B-18C6-4895-895D-28595D79AD6A

P356

Q35054958-0FB2DA09-C40F-4B47-BEB7-2EB88BF05FCB

P407

Q35054958-689E04CE-E200-4D9A-A135-7263A3403EE5

P433

Q35054958-5F57FA0B-F8CC-43F8-B85E-50DDF520ACCF

P478

Q35054958-0D968751-BE0A-4A77-B531-B5BA48FC8408

P50

Q35054958-AC982A44-943D-4329-B83D-1A58807ACF6C

P577

Q35054958-1B8451D2-736D-488D-B347-72669E48C12E

P5875

Q35054958-B92D06D2-7CB4-403B-A824-E7ED46574069

P698

Q35054958-B31B3019-94E0-4827-B68A-2B61B531C56B

P932

Q35054958-D26D12AB-A7F2-489B-990F-8C4EE38E350E

P356

P1433

The Journal of Infectious Diseases

P1476

Safety and immunogenicity of t ...... vaccine in HIV-1-infected men

@en

P2093

Alfred Saah

http://www.w3.org/2001/XMLSchema#string

David Aboulafia

http://www.w3.org/2001/XMLSchema#string

David L Cohn

http://www.w3.org/2001/XMLSchema#string

J Michael Berry

http://www.w3.org/2001/XMLSchema#string

Jeannette Y Lee

http://www.w3.org/2001/XMLSchema#string

Joel M Palefsky

http://www.w3.org/2001/XMLSchema#string

Mark H Einstein

http://www.w3.org/2001/XMLSchema#string

Naomi Jay

http://www.w3.org/2001/XMLSchema#string

Ronald T Mitsuyasu

http://www.w3.org/2001/XMLSchema#string

Shelly Y Lensing

http://www.w3.org/2001/XMLSchema#string

P2860

High prevalence of high risk human papillomavirus-capsid antibodies in human immunodeficiency virus-seropositive men: a serological study

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions

Optimization and validation of a multiplexed luminex assay to quantify antibodies to neutralizing epitopes on human papillomaviruses 6, 11, 16, and 18

Simultaneous quantitation of antibodies to neutralizing epitopes on virus-like particles for human papillomavirus types 6, 11, 16, and 18 by a multiplexed luminex assay.

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Spectrum of AIDS-associated malignant disorders.

Human papillomavirus infection and anal carcinoma. Retrospective analysis by in situ hybridization and the polymerase chain reaction.

Polymerase chain reaction detection of human papillomavirus: quantitation may improve clinical utility.

Human papillomavirus type distribution in anal cancer and anal intraepithelial lesions.

Hepatitis B vaccination in HIV-infected adults: current evidence, recommendations and practical considerations.

P304

1246-1253

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1086/656320

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

202

http://www.w3.org/2001/XMLSchema#string

P50

Elizabeth A Stier

P577

2010-10-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

46123342

http://www.w3.org/2001/XMLSchema#string

P698

20812850

http://www.w3.org/2001/XMLSchema#string

P932

3118428

http://www.w3.org/2001/XMLSchema#string